High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2

Medientyp: E-Artikel
Titel: High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2
Beteiligte: Pourcher, Valérie; Belin, Lisa; Soulie, Cathia; Rosenzwajg, Michelle; Marot, Stéphane; Lacombe, Karine; Valin, Nadia; Pialoux, Gilles; Calin, Ruxandra; Palacios, Christia; Malet, Isabelle; Zafilaza, Karen; Tubiana, Roland; Valantin, Marc-Antoine; Klatzmann, David; Calvez, Vincent; Simon-Tillaux, Noémie; Marcelin, Anne-Geneviève
Erschienen: Ovid Technologies (Wolters Kluwer Health), 2022
Erschienen in: AIDS
Sprache: Englisch
DOI: 10.1097/qad.0000000000003300
ISSN: 1473-5571; 0269-9370
Schlagwörter: Infectious Diseases ; Immunology ; Immunology and Allergy
Entstehung:
Anmerkungen:
Beschreibung: <jats:sec> <jats:title>Objectives:</jats:title> <jats:p>To assess humoral responses to SARS-CoV-2 Delta-variant in people with HIV (PWH) after BNT162b2-vaccination.</jats:p> </jats:sec> <jats:sec> <jats:title>Design:</jats:title> <jats:p>Multicenter cohort study of PWH with CD4<jats:sup>+</jats:sup> cell count less than 500 cells/μl and viral load less than 50 copies/ml on stable antiretroviral therapy for at least 3 months.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Anti-SARS-CoV-2 receptor-binding-domain IgG antibodies (anti-RBD IgG) were quantified and neutralization capacity was evaluated by ELISA/GenScript and virus-neutralization-test against the D614G-strain, beta and delta variants before vaccination (day 0) and 1 month after complete schedule (M1).</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>We enrolled 97 PWH, 85 received two vaccine shots. The seroconversion rate for anti-RBD IgG was 97% [95% confidence interval (CI) 90–100%] at M1. Median (IQR) anti-RBD IgG titer was 0.97 (0.97–5.3) BAU/ml at D0 and 1219 (602–1929) at M1. Neutralization capacity improved between D0 (15%; 50% CI 8–23%) and M1 (94%; 95% CI 87–98%) (<jats:italic toggle="yes">P</jats:italic> < 0.0001). At M1, NAbs against the D614G strain, beta and delta variants were present in 82, 77, and 84% PWH, respectively. The seroconversion rate and median anti-RBD-IgG level were 91% and 852 BAU/ml, respectively, in PWH with CD4<jats:sup>+</jats:sup> cell count less than 250 (<jats:italic toggle="yes">n</jats:italic> = 13) and 98% and 1270 BAU/ml for CD4<jats:sup>+</jats:sup>greater than 250 (<jats:italic toggle="yes">n</jats:italic> = 64) (<jats:italic toggle="yes">P</jats:italic> = 0.3994). NAbs were present in 73% of PWH with CD4<jats:sup>+</jats:sup> less than 250 and 97% of those with CD4<jats:sup>+</jats:sup> cell count greater than 250 (<jats:italic toggle="yes">P</jats:italic> = 0.0130). NAbs against beta variant were elicited in 50% in PWH with CD4<jats:sup>+</jats:sup> cell count less than 250 and in 81% of those with CD4<jats:sup>+</jats:sup> cell count greater than 250 (<jats:italic toggle="yes">P</jats:italic> = 0.0292). CD4<jats:sup>+</jats:sup> and CD8<jats:sup>+</jats:sup> T-cell counts were unchanged, whereas CD19<jats:sup>+</jats:sup> B-cell counts decreased after vaccination(208 ± 124 at D0 vs. 188 ± 112 at M1, <jats:italic toggle="yes">P</jats:italic> < 0.01). No notable adverse effects or COVID-19 cases were reported.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Seroconversion rates were high, with delta-neutralization rates similar to those for the D61G strain, after a two-dose BNT162b2 vaccination in PWH.</jats:p> </jats:sec>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: